Combined use of arginase II inhibitors and tadalafil  for the correction of monocrotaline pulmonary  hypertension

Koklin, Ivan S.; Даниленко, Л. М.

doi:10.3897/rrpharmacology.5.39522

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, one-year survival was 96% in patients with IPAH, which is 71% higher than expected survival. The REPLACE trial to replace riociguat, a soluble guanylate cyclase stimulator, with sildenafil was positive and supported the hypothesis of PDE-5 inhibition as a treatment option in patients with PH with an intermediate risk of mortality within 1 year (Tsareva and Avdeev 2013;Koklin and Danilenko 2019;Hoeper et al 2021;Liu et al 2023). Sildenafil and tadalafil are FDA approved for the treatment of PAH and are used to reduce mortality either as monotherapy or in combination with prostacyclin analogues or endothelin-1 receptor blockers.…”

Section: Pde-5 Inhibitorsmentioning

confidence: 87%

Pulmonary hypertension: modern methods of treatment and ways of their long-term development.

Zagrebelnaya,

Korokina,

Malorodova

et al. 2023

RRP

View full text Add to dashboard Cite

Introduction: The purpose of this work is to review the main pathogenetic mechanisms of the development of PH, as well as modern established methods of treatment of various types of PH and to consider new, most relevant and promising possibilities of therapy for this pathology. Etiology, pathogenesis and epidemiology: In the modern structure of diseases, pulmonary hypertension plays a significant role, affecting about 1% of the population. However, each of its five main groups has its own characteristics. The causes of pulmonary hypertension can be a polyetiological violation of the processes of endotheliocyte apoptosis and angiogenesis, passive transmission of increased pressure from the left heart to the small circulatory system, chronic hypoxia, leading to vascular remodeling, and many others. In general, it is worth noting that, despite the multiplicity of etiological factors, the main pathogenetic link in the development of pulmonary hypertension is endothelial dysfunction. Treatment and promising areas of research: This article discusses the main established approaches to the treatment of pulmonary hypertension: general recommendations for patients, drugs used as supportive nonspecific therapy, as well as specific conservative and radical methods of treatment. In addition, the main modern directions of scientific research in the field of treatment of pulmonary hypertension are described. Such promising methods as the use of stem cells, gene therapy and epigenetic drugs are considered. Conclusion: Despite active research and many different drugs intended for the treatment of pulmonary hypertension, this pathological condition remains an urgent health problem. Thus, the search for new points of application of therapy and fundamentally new methods of treatment of pulmonary hypertension remains relevant to this day.

show abstract

Section: Pde-5 Inhibitorsmentioning

confidence: 87%

Pulmonary hypertension: modern methods of treatment and ways of their long-term development.

Zagrebelnaya,

Korokina,

Malorodova

et al. 2023

RRP

View full text Add to dashboard Cite

show abstract

“…The direct connection between the development of endothelial dysfunction and the formation of cardiovascular pathology is the fact proved by many experimental and clinical studies (Demougeot et al 2005;Morris et al 2005;Yakushev et al 2015;Koklin and Danilenko 2019). Ludmer et al (1988) in their unique work described the vasoconstrictive effect of acetylcholine in patients with atherosclerosis.…”

Section: Role Of Arginase 2 In the Development Of A Number Of Cardiovmentioning

confidence: 98%

Role of Arginase 2 as a potential pharmacological target for the creation of new drugs to correct cardiovascular diseases

Demchenko¹,

Koklin²,

Koklina³

2020

RRP

Self Cite

View full text Add to dashboard Cite

Introduction: The review provides relevant information about arginase 2, the role of this enzyme in the formation of endothelial dysfunction and, as a consequence, the development of cardiovascular diseases. History of the discovery of arginase and its functions: The discovery of arginase took place long before its active study as a substance that affects the formation of endothelial dysfunction. Role of arginase 2 in the development of a number of cardiovascular diseases: The role of NO synthase and arginase 2 in the formation of oxidative stress is determined. The pathophysiological mechanisms of the development of a number of cardiovascular diseases, such as coronary heart disease, atherosclerosis, and aortic aneurysm, are described. The modern possibilities of treatment of endothelial dysfunction in the pathology of the cardiovascular system and the possibility of creation of new drugs are considered. An increase in the activity of arginase 2 was proven to occur in the case of the development of coronary heart disease (CHD), hypertension, type II diabetes mellitus, hypercholesterolemia, as well as in the process of aging. According to the WHO, coronary heart disease and apoplectic attack have topped the list of causes of death worldwide over the past 15 years. Arginase 2 as a potential pharmacological target: The purpose of this literature review is to determine the possibilities of use of arginase 2 as a new target for the pharmacological correction of cardiovascular diseases.

show abstract

“…Furthermore, combining L207-0525 and L327-0346 with low dose (0.1 mg/kg) tadalafil produced a better protective effect in monocrotakine-induced PAH rats. Therefore, L207-0525 and L327-0346 are potential compounds needing further exploration for PAH treatment ( Koklin and Danilenko, 2019 ).…”

Section: Ongoing Pharmaceutical Research On Nitric Oxide Pathway and Its Implication In Pulmonary Arterial Hypertensionmentioning

confidence: 99%

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Tettey

Jiang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.

show abstract

Combined use of arginase II inhibitors and tadalafil for the correction of monocrotaline pulmonary hypertension

Cited by 4 publications

References 28 publications

Pulmonary hypertension: modern methods of treatment and ways of their long-term development.

Pulmonary hypertension: modern methods of treatment and ways of their long-term development.

Role of Arginase 2 as a potential pharmacological target for the creation of new drugs to correct cardiovascular diseases

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Contact Info

Product

Resources

About